Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

cemiplimab

- PMLiVE

Sanofi on track to refile Lyxumia in US

Study showed drug was equivalent to placebo in cardiovascular safety

- PMLiVE

Keytruda is UK’s first early-access medicine

Merck’s melanoma therapy accepted under the UK’s EAMS

- PMLiVE

Cancer Drugs Fund cull ‘won’t save NHS money’

New survey also finds that oncologists believe the cuts will ‘worsen patient outcomes’

Sanofi names Robert Castaigne as audit committee chairman

He succeeds Dr Klaus Pohle

- PMLiVE

US approval for Astellas’ new antifungal drug Cresemba

Japanese firm co-markets the azole antifungal agent with Basilea

- PMLiVE

FDA approves first biosimilar

Novartis’ Sandoz unit gains new licence for Neupogen copycat

- PMLiVE

Merck and Eisai link up on anti-PD-1 combinations

Will test Keytruda with both Lenvima and Halaven 

Bristol-Myers Squibb (BMS) building

Opdivo gains new US lung cancer licence

Adds to Bristol-Myers Squibb’s therapeutic vaccine’s melanoma indication

FDA launches drug shortages mobile app

USregulator offers the public and HCPs Android and iPhone versions of the app

EU flag

New cancer meds and drug extensions top CHMP recommendations

Drugs for rare disease, oncology and diabetes top regulator’s endorsements

Ex Sanofi boss joins Boston start-up

Chris Viehbacher joins other industry veterans as the newest board member of PureTech

Sanofi reception

Sanofi’s Lantus follow-up nears European approval

CHMP backing for Toujeo follows hot on the heels of its US approval by the FDA

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links